Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML

NCT05048498 is registered in ClinicalTrials.gov with Nanexa AB as lead sponsor.

NCT NCT05048498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05048498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML
Lead sponsor
Nanexa AB
Phase
Phase 1
Overall status
Completed
Start date
April 27, 2021
Completion date
February 10, 2022
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic myelomonocytic leukemia (cmml), myelodysplastic syndromes (mds)